Literature DB >> 32559113

Multimodality imaging of adult rhabdomyosarcoma: the added value of hybrid imaging.

Nicolò Gennaro1,2, Andrea Marrari1,3, Salvatore Lorenzo Renne1,4, Ferdinando Carlo Maria Cananzi1,5, Vittorio Lorenzo Quagliuolo5, Lucia Di Brina6, Marta Scorsetti1,6,1, Giovanna Pepe7, Arturo Chiti1,1,7, Armando Santoro1,3,1, Luca Balzarini2, Letterio Salvatore Politi1,8,9,10, Alexia Francesca Bertuzzi3.   

Abstract

Rhabdomyosarcoma (RMS) represents more than 50% of paediatric soft tissue tumours. Conversely, it is extremely rare among adults, where it shows peculiar biological and clinical features that are still poorly investigated. RMS patients should be referred to a Sarcoma Centre, where the contribution of experienced radiologists plays a relevant role in the diagnostic assessment of the disease, including precise localisation, staging, image-guided biopsy, response evaluation after treatment and follow-up. Besides CT and MRI, hybrid imaging including positron emission tomography (PET)/CT and PET/MRI are giving an increasing contribution to provide functional insights about tumour biology and to improve the diagnostic accuracy of the imaging work-up. This review paper provides a revision of the pathology, clinical and radiological features of adult RMS, with a particular focus on the growing role of hybrid PET-based imaging.

Entities:  

Mesh:

Year:  2020        PMID: 32559113      PMCID: PMC7446015          DOI: 10.1259/bjr.20200250

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  39 in total

1.  Rhabdomyosarcoma in adolescents: a report from the AIEOP Soft Tissue Sarcoma Committee.

Authors:  Gianni Bisogno; Alessia Compostella; Andrea Ferrari; Guido Pastore; Giovanni Cecchetto; Alberto Garaventa; Paolo Indolfi; Luigi De Sio; Modesto Carli
Journal:  Cancer       Date:  2011-07-12       Impact factor: 6.860

2.  Transfer learning on fused multiparametric MR images for classifying histopathological subtypes of rhabdomyosarcoma.

Authors:  Imon Banerjee; Alexis Crawley; Mythili Bhethanabotla; Heike E Daldrup-Link; Daniel L Rubin
Journal:  Comput Med Imaging Graph       Date:  2017-05-05       Impact factor: 4.790

3.  Hybrid PET/MR imaging in two sarcoma patients - clinical benefits and implications for future trials.

Authors:  Sasan Partovi; Andres A Kohan; Lisa Zipp; Peter Faulhaber; Christos Kosmas; Pablo R Ros; Mark R Robbin
Journal:  Int J Clin Exp Med       Date:  2014-03-15

Review 4.  Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review.

Authors:  Hui Jun Lim; Chin-Ann Johnny Ong; Joey Wee-Shan Tan; Melissa Ching Ching Teo
Journal:  Crit Rev Oncol Hematol       Date:  2019-07-21       Impact factor: 6.312

Review 5.  The current landscape of rhabdomyosarcomas: an update.

Authors:  Julia Leiner; François Le Loarer
Journal:  Virchows Arch       Date:  2019-11-06       Impact factor: 4.064

6.  Multiparametric Assessment of Treatment Response in High-Grade Soft-Tissue Sarcomas with Anatomic and Functional MR Imaging Sequences.

Authors:  Theodoros Soldatos; Shivani Ahlawat; Elizabeth Montgomery; Majid Chalian; Michael A Jacobs; Laura M Fayad
Journal:  Radiology       Date:  2015-09-21       Impact factor: 11.105

Review 7.  Practical guide for implementing hybrid PET/MR clinical service: lessons learned from our experience.

Authors:  Nainesh Parikh; Kent P Friedman; Shetal N Shah; Hersh Chandarana
Journal:  Abdom Imaging       Date:  2015-08

8.  Who, how and what of pathology of soft tissue sarcoma.

Authors:  Salvatore Lorenzo Renne
Journal:  Chin Clin Oncol       Date:  2018-11-09

9.  Analysis of pulmonary nodules in patients with high-grade soft tissue sarcomas.

Authors:  Tomoki Nakamura; Akihiko Matsumine; Miki Matsusaka; Keitaro Mizumoto; Mayuko Mori; Tomoya Yoshizaki; Takao Matsubara; Kunihiro Asanuma; Akihiro Sudo
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

10.  The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols.

Authors:  R B Raney; H M Maurer; J R Anderson; R J Andrassy; S S Donaldson; S J Qualman; M D Wharam; E S Wiener; W M Crist
Journal:  Sarcoma       Date:  2001
View more
  5 in total

1.  Clinical and pathological characteristics, treatment outcome and prognostic factors in adult rhabdomyosarcoma: a monocentric retrospective study.

Authors:  Myriam Saadi; Feryel Letaief; Azza Gabsi; Amina Mokrani; Khedija Meddeb; Amel Mezlini
Journal:  Pan Afr Med J       Date:  2022-03-25

2.  Metabolic response as assessed by 18 F-fluorodeoxyglucose positron emission tomography-computed tomography does not predict outcome in patients with intermediate- or high-risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee.

Authors:  Douglas J Harrison; Yueh-Yun Chi; Jing Tian; Pooja Hingorani; Leo Mascarenhas; Geoffrey B McCowage; Brenda J Weigel; Rajkumar Venkatramani; Suzanne L Wolden; Torunn I Yock; David A Rodeberg; Andrea A Hayes-Jordan; Lisa A Teot; Sheri L Spunt; William H Meyer; Douglas S Hawkins; Barry L Shulkin; Marguerite T Parisi
Journal:  Cancer Med       Date:  2020-12-19       Impact factor: 4.452

3.  Proof of concept of a multimodal intravital molecular imaging system for tumour transpathology investigation.

Authors:  Zhen Liu; Tao Cheng; Stephan Düwel; Ziying Jian; Geoffrey J Topping; Katja Steiger; Qian Wang; Rickmer Braren; Sybille Reder; Markus Mittelhäuser; Christian Hundshammer; Benedikt Feuerecker; Sung-Cheng Huang; Markus Schwaiger; Franz Schilling; Sibylle I Ziegler; Kuangyu Shi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-10-15       Impact factor: 9.236

4.  GEIS-SEHOP clinical practice guidelines for the treatment of rhabdomyosarcoma.

Authors:  S Gallego; D Bernabeu; M Garrido-Pontnou; G Guillen; N Hindi; A Juan-Ribelles; C Márquez; C Mata; J Orcajo; G Ramírez; M Ramos; C Romagosa; D Ruano; P Rubio; R Vergés; C Valverde
Journal:  Clin Transl Oncol       Date:  2021-07-01       Impact factor: 3.405

5.  Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT.

Authors:  Stefan A Koerber; R Finck; K Dendl; M Uhl; T Lindner; C Kratochwil; M Röhrich; H Rathke; G Ungerechts; S Adeberg; K Herfarth; D Jaeger; J Debus; U Haberkorn; F L Giesel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-05-21       Impact factor: 9.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.